Skip to main content
  • Register
  • Help
  • Contact us

Onconova Therapeutics Inc (ONTX) Ordinary Shares

Sell:$0.59 Buy:$0.61 Change: $0.0018 (0.30%)
Market closed |  Prices as at close on 7 May 2021 | Switch to live prices |
Sell:$0.59
Buy:$0.61
Change: $0.0018 (0.30%)
Market closed |  Prices as at close on 7 May 2021 | Switch to live prices |
Sell:$0.59
Buy:$0.61
Change: $0.0018 (0.30%)
Market closed |  Prices as at close on 7 May 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells. It has over three clinical-stage product candidates and various preclinical programs that target kinases, cellular metabolism or cell division in preclinical development. The Company's lead product candidate, rigosertib, is being tested in both intravenous (IV) and oral formulations as a single agent, and the oral formulation is also being tested in combination with azacitidine, in clinical trials for patients with myelodysplastic syndromes (MDS), and related cancers. Its other product candidates include Briciclib and Recilisib.

Contact details

Address:
375 Pheasant Run
NEWTOWN
18940-3423
United States
Telephone:
+1 (267) 7593680
Website:
https://www.onconova.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ONTX
ISIN:
US68232V4059
Market cap:
$145.19 million
Shares in issue:
236.61 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • James Marino
    Chairman of the Board
  • Steven Fruchtman
    President, Chief Executive Officer, Director
  • Mark Guerin
    Chief Financial Officer
  • Abraham Oler
    Vice President, Corporate Development and General Counsel

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.